IL17A

(redirected from interleukin-17A)

IL17A

A gene on chromosome 6p12 that encodes interleukin-17A, a proinflammatory cytokine produced by activated T cells which regulates NF-kappaB and mitogen-activated protein kinases. It upregulates IL6 and cyclooxygenase-2 and increases nitric oxide production.

Molecular pathology
IL17A is overexpressed in rheumatoid arthritis, psoriasis and multiple sclerosis.

References in periodicals archive ?

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.

Comparative effectiveness of secukinumab and etanercept in biologic-naive patients with psoriatic arthritis assessed by matching-adjusted indirect comparison

The product is claimed to be the first and only fully-human biologic, which directly restricts interleukin-17A (IL-17A), a cornerstone cytokine engaged in the inflammation and development of PsA, psoriasis, and ankylosing spondylitis.

Novartis' Cosentyx achieves endpoints in psoriatic arthritis study

Novartis announced that the China Health Authority NMPA approved Cosentyx, the first-in-class interleukin-17A inhibitor for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Novartis announces Chinese approval of Cosentyx for psoriasis patients

The rationale for investigating secukinumab (Cosentyx), a biologic that blocks the interleukin-17A receptor and is approved for treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis, lies in the observation that HS lesions exhibit an increased ratio of Th17- to T-regulatory cells, compared with normal skin.

Secukinumab shows promise in hidradenitis suppurativa

Cosentyx is the first and only fully-human treatment that specifically inhibits interleukin-17A (IL-17A), in psoriatic arthritis (PsA).

Switzerland : Novartis receives approval for Cosentyx label update in Europe to include dosing flexibility in psoriatic arthritis

According to the researches, targeting this molecule, interleukin-17a, offered another potential avenue for preventing autism in people.

Mother's gut holds answer to autism

The company said Cosentyx is a fully human monoclonal antibody (mAB) that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.

Novartis passes US FDA approval of Cosentyx for inclusion of new evidence in slowing down joint structural damage in psoriatic arthritis

This agent may work through inhibiting proinflammatory mediators including interleukin-6 and interleukin-17A. The topical 1% cream is being studied for both AD and psoriasis.

Systemic corticosteroids not recommended for long-term treatment of atopic dermatitis

Protective immunity against recurrent Staphylococcus aureus skin infection requires antibody and interleukin-17A. Infect Immun 2014; 82: 2125-2134, doi: 10.1128/IAI.01491-14.

Individual variation is the key to the development of a vaccine against Staphylococcus aureus: a comparative study between mice lineages

Volz, "Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab," Acta Dermato-Venereologica, vol.

Therapeutic Response to Secukinumab in a 36-Year-Old Woman with Hidradenitis Suppurativa

Peck, "Pathogenic effect of interleukin-17A in induction of Sjogren's syndrome-like disease using adenovirus-mediated gene transfer," Arthritis Research & Therapy, vol.

Expression of G[alpha]q Is Decreased in Lymphocytes from Primary Sjogren's Syndrome Patients and Related to Increased IL-17A Expression

Interleukin-17A (IL-17A) participates in the pathogenesis of several immune and inflammatory diseases and upregulates expression of numerous inflammation-related genes [42].

Association of Optic Neuritis with CYP4F2 Gene Single Nucleotide Polymorphism and IL-17A Concentration